Core Laboratories posted Q1 2026 revenue of $121.8 million, flat year-over-year but down 12% sequentially, with GAAP loss per share of $0.02 due to operational disruptions from Middle East geopolitical conflicts and severe weather. The company saw a 58% sequential drop in operating income ex-items to $6.6 million and free cash flow of $0.5 million. Despite challenges, Core Labs expects modest sequential improvement in Q2 and continues to advance proprietary technologies while maintaining a focus on long-term shareholder value. The company also announced a quarterly dividend of $0.01 per share for Q2 2026.
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
Worldline has announced a conference call to discuss its H1 2026 financial results on July 30, 2026, at 6:30 pm CET. The event will be accessible via webcast, and sell-side analysts can participate in a Q&A session by pre-registering. The press relea...
Ipsen Pharma conducted a share buy-back program from July 6 to July 10, 2026, repurchasing a total of 28,541 shares. The average purchase price during this period was €166.05 per share. This buy-back activity reflects Ipsen's strategy to manage its c...
